A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Trial Profile

A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Criterium
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 1 Aug 2017 to 30 Mar 2018.
    • 16 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Dec 2017.
    • 24 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top